Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chamber crossover clinical trial of Reproxalap for dry eyes

Next Previous
Trial Profile

Chamber crossover clinical trial of Reproxalap for dry eyes

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reproxalap (Primary)
  • Indications Dry eyes
  • Focus Registrational; Therapeutic Use
  • Sponsors Aldeyra Therapeutics

Most Recent Events

  • 05 May 2025 According to Aldeyra Therapeutics Media Release, company will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce topline results from Phase 3 dry eye disease.
  • 13 Jun 2024 According to an Aldeyra Therapeutics media release, company intends to include in the potential NDA resubmission a draft label for reproxalap describing chronic and acute improvement in symptoms and ocular redness. As per FDA guidance, the review period for the potential NDA resubmission is expected to be six months.
  • 13 Jun 2024 According to an Aldeyra Therapeutics media release, company anticipates receiving results from the clinical trial in the third quarter of 2024, and, contingent on positive results, and remain on track to resubmit the dry eye disease NDA for reproxalap in the second half of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top